durvalumab — drug repurposing hypotheses

CROSS-DOMAIN PATTERN

Same drug, multiple disease domains

durvalumab appears in hypotheses across 3 disease domains: Glioblastoma, Inflammatory bowel disease, Rheumatoid arthritis. Shared mediators that recur across at least two of those domains: PD-L1.

Aggregated from the catalog. Biological interpretation of any multi-indication mechanism would require independent validation — this is a structural observation only.

ALL HYPOTHESES

Repurposing candidates for durvalumab

Glioblastoma 11

Mediator	Outcome	Score	Tier	Lit. status	Trial
PD-L1	overall survival	0.248	Mid	reproduces known	active
PD-L1	Glioblastoma multiforme	0.208	Mid	novel signal	active
PD-L1	worse overall survival	0.208	Mid	partial evidence	none
PD-L1	clinical response	0.208	Mid	reproduces known	completed
PD-L1	treatment resistance	0.208	Mid	reproduces known	active
PD-L1	longer survival	0.208	Mid	reproduces known	none
PD-L1	prognosis	0.208	Mid	reproduces known	active
PD-L1	long-term survival	0.208	Mid	reproduces known	completed
PD-L1	worse progression-free survival	0.208	Mid	partial evidence	none
PD-L1	immune control	0.208	Mid	partial evidence	completed
PD-L1	survival	0.208	Mid	reproduces known	active

Inflammatory bowel disease 4

Mediator	Outcome	Score	Tier	Lit. status	Trial
PD-L1	colitis	0.248	Mid	reproduces known	none
PD-L1	PD-1 inhibitor-associated colitis	0.208	Mid	novel signal	none
PD-L1	inflammatory damage	0.208	Mid	novel signal	none
PD-L1	gut microbiota composition	0.208	Mid	novel signal	none

Rheumatoid arthritis 2

Mediator	Outcome	Score	Tier	Lit. status	Trial
PD-L1	T cell infiltration	0.208	Mid	reproduces known	completed
PD-L1	joint swelling	0.208	Mid	novel signal	none

← All drugs